8 completed, 5 unknown, 4 not yet recruiting, 3 enrolling by invitation. 7 Phase 2, 6 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Medullary Thyroid Carcinoma: new trials by email Literature Review of Medullary Thyroid Carcinoma trials Research Report on Medullary Thyroid Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT - Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma | Not yet recruiting | British Columbia Cancer Agency | 60 | 2026-11-30 | 2026-10-06 | |
| Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid Cancer lobectomy with lymph node dissection - Medullary Thyroid Carcinoma | Not yet recruiting | Aristotle University Of Thessaloniki | 74 | 2026-09-30 | 2026-10-01 | |
| Thyroid Health Outcomes Registry for Surgery Thyroid Diseases, Thyroid Neoplasms | Not yet recruiting | Pirogov Russian National Research Medical University | 3000 | 2026-09-01 | 2026-09-10 | |
| Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma No treatment given - Medullary Thyroid Carcinoma | Enrolling by invitation | Novo Nordisk A/S | 93600000 | 2025-12-31 | 2026-08-04 | |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC 68Ga-CTR-FAPI PET-CT guided surgery, investigator choice of surgery - Medullary Thyroid Carcinoma | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 150 | 2025-08-25 | 2026-02-03 |
| Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC 68Ga-DOTA-CCK-FS PET/CT - Medullary Thyroid Carcinoma | Not applicable | Recruiting | Luo Yaping | 30 | 2025-05-10 | 2025-08-24 |
| PET-TC in Thyroid Evaluation clinical practice drug treatment - Medullary Thyroid Carcinoma, Hyperparathyroidism | Enrolling by invitation | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 418 | 2024-10-14 | 2025-02-28 | |
| Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Lu-177 DOTATATE (Lutathera®) - Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma | Phase 2 | Not yet recruiting | University College, London | 110 | 2023-12-18 | 2023-12-07 |
| Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma 68Ga-MGS5 - Medullary Thyroid Carcinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 20 | 2023-06-21 | 2024-07-25 |
| Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer 18F-PSMA-1007 - Medullary Thyroid Cancer, Medullary Thyroid Carcinoma | Not applicable | Completed | University Medical Center Groningen | 8 | 2022-08-19 | 2025-06-24 |
| A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) HA121-28 tablets - Medullary Thyroid Carcinoma | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 30 | 2021-07-13 | 2022-02-23 |
| Spanish Study for Molecular Characterization of Thyroid Carcinoma Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes - Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma | Unknown | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | 150 | 2021-06-14 | 2024-09-19 | |
| Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma PET at 18F-FDOPA - Medullary Thyroid Carcinoma | Not applicable | Unknown | Assistance Publique Hopitaux De Marseille | 62 | 2018-10-01 | 2018-08-17 |
| Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement - Medullary Thyroid Carcinoma, Nodular Goiter | Completed | Austral University, Argentina | 155 | 2018-03-01 | 2023-10-06 | |
| Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC 111In-CP04, 111In-CP04 with co-administration of gelofusine/gelaspan - Medullary Thyroid Carcinoma | Phase 1 | Completed | Paola Anna Erba | 16 | 2016-08-01 | 2020-03-20 |
| Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Anlotinib, Placebo - Medullary Thyroid Carcinoma | Phase 2 / Phase 3 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 91 | 2015-07-01 | 2019-05-21 |
| ImmunoTEP for Patients With Medullary Thyroid Carcinoma. • TF2 and 68 Ga-IMP-288 - Medullary Thyroid Carcinoma | Phase 1 / Phase 2 | Completed | Nantes University Hospital | 25 | 2013-01-01 | 2022-07-26 |
| Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma Sorafenib - Medullary Thyroid Carcinoma | Phase 2 | Withdrawn | Eanm Research Ltd | 2012-10-01 | 2013-05-17 | |
| An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) No treatment given - Diabetes, Diabetes Mellitus, Type 2 | Enrolling by invitation | Novo Nordisk A/S | 6750 | 2012-01-01 | 2023-06-13 |
Showing 20 of 25. Sign in to see all of them.
Carcinoma, Medullary (25) · Thyroid Neoplasms (3) · Multiple Endocrine Neoplasia Type 2a (2) · Paraganglioma (2) · Pheochromocytoma (2) · Thyroid Diseases (2) · Adrenal Gland Neoplasms (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Merkel Cell (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Goiter (1) · Goiter, Nodular (1)
Adenocarcinoma (25) · Carcinoma (25) · Carcinoma, Neuroendocrine (25) · Neoplasms by Histologic Type (25) · Neoplasms, Ductal, Lobular, and Medullary (25) · Neoplasms, Germ Cell and Embryonal (25) · Neoplasms, Glandular and Epithelial (25) · Neoplasms, Nerve Tissue (25) · Neuroectodermal Tumors (25) · Neoplasms (24) · Neuroendocrine Tumors (24) · Endocrine System Diseases (9) · Neoplasms by Site (8) · Endocrine Gland Neoplasms (6) · Head and Neck Neoplasms (4)
vandetanib (2) · Bortezomib (1) · High-Throughput Nucleotide Sequencing (1) · Immunohistochemistry (1) · In Situ Hybridization, Fluorescence (1) · Lymph Node Excision (1) · Sorafenib (1) · anlotinib (1) · gallium Ga 68 dotatate (1) · lutetium Lu 177 dotatate (1)
National Cancer Institute (NCI) (4) · Novo Nordisk A/S (2) · Aristotle University Of Thessaloniki (1) · Assistance Publique Hopitaux De Marseille (1) · Austral University, Argentina (1) · British Columbia Cancer Agency (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Eanm Research Ltd (1) · First Affiliated Hospital of Fujian Medical University (1) · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Luo Yaping (1) · Nantes University Hospital (1)
United States (7) · China (5) · Canada (3) · France (2) · Germany (2) · Netherlands (2) · Argentina (1) · Austria (1) · Italy (1) · Japan (1) · Poland (1) · Slovenia (1) · South Korea (1) · Spain (1)
Annette Stemhagen, DrPH, FISPE (1) · Antonio T Fojo, M.D. (1) · Brigitte C Widemann, M.D. (1) · Daniel Worsley, MD (1) · Francoise Bodere, PhD, MD (1) · Ian Alberts, MBBS MD PhD FEBNM (1) · Paola Anna Erba, Professor (1) · Ravi A Madan, M.D. (1) · Shaoyan Liu, MD (1) · Weibing Miao (1) · Wen Xu, Master (1) · William D Figg, Pharm.D. (1)
PMID 15999359, PMID 17405835, PMID 21358115, PMID 23766359, PMID 24617713, PMID 24848831, PMID 25810047, PMID 25972901, PMID 26462967, PMID 29187393, PMID 30297385, PMID 30450128, PMID 30637562, PMID 33179845, PMID 36877452, PMID 38047535, PMID 38778111, PMID 39470165